Concepts (76)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Receptor, Adenosine A2A | 4 | 2018 | 6 | 1.210 |
Why?
|
| Caffeine | 2 | 2016 | 81 | 1.030 |
Why?
|
| Conditioning, Operant | 4 | 2017 | 241 | 0.950 |
Why?
|
| Cocaine | 5 | 2018 | 555 | 0.940 |
Why?
|
| Drug-Seeking Behavior | 5 | 2018 | 213 | 0.880 |
Why?
|
| Receptor, Adenosine A1 | 4 | 2014 | 8 | 0.860 |
Why?
|
| Dopamine Uptake Inhibitors | 2 | 2014 | 152 | 0.820 |
Why?
|
| Cocaine-Related Disorders | 3 | 2018 | 504 | 0.650 |
Why?
|
| Extinction, Psychological | 4 | 2017 | 240 | 0.570 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2016 | 150 | 0.530 |
Why?
|
| Dopamine Agonists | 5 | 2018 | 68 | 0.530 |
Why?
|
| Pituitary-Adrenal System | 1 | 2016 | 138 | 0.530 |
Why?
|
| Nucleus Accumbens | 4 | 2014 | 417 | 0.530 |
Why?
|
| Anxiety | 1 | 2016 | 422 | 0.440 |
Why?
|
| Adenosine A2 Receptor Agonists | 4 | 2018 | 4 | 0.430 |
Why?
|
| Locomotion | 3 | 2018 | 135 | 0.370 |
Why?
|
| Aging | 1 | 2016 | 911 | 0.360 |
Why?
|
| Self Administration | 7 | 2018 | 419 | 0.360 |
Why?
|
| Quinpirole | 3 | 2014 | 26 | 0.360 |
Why?
|
| Rats, Sprague-Dawley | 7 | 2018 | 2083 | 0.350 |
Why?
|
| Rats | 8 | 2018 | 5300 | 0.350 |
Why?
|
| Adenosine A2 Receptor Antagonists | 2 | 2018 | 4 | 0.290 |
Why?
|
| Receptors, Dopamine D2 | 2 | 2018 | 109 | 0.280 |
Why?
|
| Adenosine | 4 | 2014 | 165 | 0.270 |
Why?
|
| Phenethylamines | 3 | 2014 | 20 | 0.260 |
Why?
|
| Methamphetamine | 2 | 2018 | 132 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1745 | 0.260 |
Why?
|
| Animals | 9 | 2018 | 20877 | 0.200 |
Why?
|
| Encephalitis | 1 | 2017 | 43 | 0.150 |
Why?
|
| Ventral Tegmental Area | 1 | 2017 | 74 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2017 | 156 | 0.140 |
Why?
|
| Male | 9 | 2018 | 37281 | 0.140 |
Why?
|
| Central Nervous System Stimulants | 2 | 2018 | 221 | 0.140 |
Why?
|
| Paraventricular Hypothalamic Nucleus | 1 | 2016 | 15 | 0.140 |
Why?
|
| Corticosterone | 1 | 2016 | 51 | 0.140 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2016 | 106 | 0.140 |
Why?
|
| Pyrazoles | 2 | 2014 | 190 | 0.140 |
Why?
|
| Pyrimidines | 2 | 2014 | 178 | 0.140 |
Why?
|
| Corticotropin-Releasing Hormone | 1 | 2016 | 79 | 0.130 |
Why?
|
| Receptors, Adenosine A2 | 1 | 2014 | 1 | 0.130 |
Why?
|
| Food Preferences | 1 | 2014 | 46 | 0.130 |
Why?
|
| Adenosine A1 Receptor Agonists | 1 | 2014 | 2 | 0.120 |
Why?
|
| Amygdala | 1 | 2016 | 159 | 0.120 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2014 | 82 | 0.120 |
Why?
|
| Behavior, Animal | 1 | 2016 | 470 | 0.110 |
Why?
|
| Receptors, Dopamine D1 | 1 | 2013 | 87 | 0.110 |
Why?
|
| Receptors, AMPA | 1 | 2013 | 99 | 0.110 |
Why?
|
| Purinergic P2X Receptor Antagonists | 1 | 2011 | 2 | 0.110 |
Why?
|
| Xanthines | 1 | 2011 | 17 | 0.110 |
Why?
|
| Dopamine | 1 | 2014 | 474 | 0.110 |
Why?
|
| Sweetening Agents | 1 | 2011 | 23 | 0.100 |
Why?
|
| Sucrose | 1 | 2011 | 58 | 0.100 |
Why?
|
| Recurrence | 1 | 2014 | 948 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 1860 | 0.090 |
Why?
|
| Cues | 1 | 2014 | 654 | 0.090 |
Why?
|
| Stress, Psychological | 1 | 2016 | 824 | 0.090 |
Why?
|
| Analysis of Variance | 1 | 2011 | 1039 | 0.090 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1293 | 0.080 |
Why?
|
| Purinergic P1 Receptor Agonists | 2 | 2014 | 7 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 2550 | 0.060 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 88 | 0.040 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2017 | 114 | 0.040 |
Why?
|
| Motor Activity | 1 | 2018 | 621 | 0.030 |
Why?
|
| Reinforcement Schedule | 1 | 2014 | 59 | 0.030 |
Why?
|
| 6-Cyano-7-nitroquinoxaline-2,3-dione | 1 | 2013 | 12 | 0.030 |
Why?
|
| alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2013 | 21 | 0.030 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 2013 | 59 | 0.030 |
Why?
|
| Microinjections | 1 | 2013 | 130 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1663 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 128 | 0.030 |
Why?
|
| Benzazepines | 1 | 2013 | 104 | 0.030 |
Why?
|
| Drug Interactions | 1 | 2013 | 289 | 0.030 |
Why?
|
| Gene Transfer Techniques | 1 | 2013 | 173 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2013 | 1199 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 2688 | 0.020 |
Why?
|
| Humans | 1 | 2014 | 68525 | 0.020 |
Why?
|